NeuroSense Therapeutics Ltd. income statement NRSNW

Annual Quarterly

It recorded a net loss of $11.1 million. Diluted earnings per share were -$0.44.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
Research and development
6
+9.3%
6
Selling, general and administrative
5
+15.6%
4
-12.0%
Operating income
-11
-11.9%
-10
Net income
-11
-9.0%
-10
Basic EPS
-0.44
+18.5%
-0.54
Diluted EPS
-0.44
+18.5%
-0.54
Weighted average shares, basic
25
+37.0%
19
Weighted average shares, diluted
25
+37.0%
19
Other measures
Depreciation and amortization
0
-27.3%
0
EBITDA
-11
-12.0%
-10
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
NRSN (Nasdaq), NRSNW (Nasdaq)
Fiscal year ends
December 31
Incorporated in
Israel
Headquarters
Herzliya, Israel
SEC filer status
Non-accelerated filer, Emerging growth company
SEC CIK
1875091

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.